Clinical Trials on Intellectual Disability in Russian Federation

Total 5 results

AO GENERIUM

Completed

A Multi-cohort Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers

Metabolic Diseases | Mucopolysaccharidosis Type II

Russian Federation
AO GENERIUM

Recruiting

A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II

Metabolic Diseases | Mucopolysaccharidosis Type II

Russian Federation
Federal Research Institute of Pediatric Hematology...

Unknown

Creating a Decision Support System for the Corporate Management of Physical Therapy

Physical Activity | Physical Disability | Childhood Acute Lymphoblastic Leukemia in Remission | Childhood Brain Tumor

Russian Federation
NeuroVia, Inc.

Withdrawn

Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy

X-Linked Adrenoleukodystrophy

Australia, Argentina, United Kingdom, Colombia, Chile, France, Russian Federation, Ukraine
Merz Pharmaceuticals GmbH

Completed

Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability (SIPEXI)

Stroke | Cerebral Palsy | Intellectual Disability | Traumatic Brain Injury | Chronic Troublesome Sialorrhea

Georgia, Hungary, Poland, Russian Federation, Serbia, Ukraine

3

Subscribe